On May 13, at 16.00, the Foundation for Advanced Biomedical Research VIMM hosted the “Stanley J. Korsmeyer Lecture” given every year by the winner of the Pezcoller Foundation-AACR International Award For Cancer Research, the International Prize for scientific research in the field of oncology, established by the Trento Pezcoller Foundation and by the American Association for Cancer Research.
This year the prize was awarded to James P. Allison, immunologist, director of the Anderson Cancer Center at the Houston University.
His research in 1990 at the University of California, Berkeley, led the clinical development of ipilimumab, which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Dr. Allison is studying another molecule capable of inhibiting the activity of T lymphocytes in certain types of cancer with the worst prognosis.
The “Stanley J. Korsmeyer Lecture” was established by the Foundation for Advanced Biomedical Research in memory of Stanley J.Korsmeyer, internationally renowned researcher, who won the Pezcoller-AARC prize in 2004, who died in 2005 when he was only 55 years old. Stanley Korsmeyer for years has been a point of reference for the research carried out by many researchers working at the Advanced Biomedical Research Foundation-VIMM.